France’s MedDay says drug for MS falls at phase 3 hurdleMedDay Pharma has been unable to replicate promising results with its multiple sclerosis therapy MD1003 in a confirmatory Share XFrance’s MedDay says drug for MS falls at phase 3 hurdlehttps://pharmaphorum.com/news/frances-medday-says-drug-for-ms-falls-at-phase-3-hurdle/
